Clinical Trial Update: A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients [Phase 2]

View source ↗

Summary

Phase 2 single ascending-dose study of reconstituted high-density lipoprotein CSL112 in patients with stable atherothrombotic disease assessed safety and pharma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• CSL112

Snippet

Sponsor: CSL Limited | Conditions: Stable Atherothrombotic Disease | Phase 2 | Status: COMPLETED